# Royalty Pharma Sub-Manager, LLC: Form 13F holdings

An institutional investment manager in New York, NY. SEC CIK 2081668.

- Quarter ended: 2026-06-30
- Filed: 2026-08-21
- Reported value: $241.9m
- Positions: 4 (4 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/2081668/000208166826000018/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [CYTOKINETICS, INC (CYTK)](/companies/cytk.md) | COM | $83.5m | 34.5% | 980,392 |  | Unchanged |
| [ZENAS BIOPHARMA, INC. (ZBIO)](/companies/zbio.md) | COM | $60.6m | 25.1% | 2,388,150 |  | New +2,388,150 |
| [KAILERA THERAPEUTICS (KLRA)](/companies/klra.md) | COM | $54.1m | 22.4% | 2,455,357 |  | New +2,455,357 |
| BIOHAVEN LTD | COM | $43.7m | 18.1% | 2,936,507 |  | Unchanged |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [BIOCRYST PHARMACEUTICALS INC (BCRX)](/companies/bcrx.md) | COM | $0 | 0.0% | 0 |  | Sold out −3,846,154 |
| [ZENAS BIOPHARMA, INC. (BCAX)](/companies/bcax.md) | COM | $0 | 0.0% | 0 |  | Sold out −2,388,150 |

Source: SEC EDGAR, Form 13F-HR, accession 0002081668-26-000018. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.